• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

癌症中成纤维细胞生长因子受体IgIII环的可变剪接

Alternative Splicing of Fibroblast Growth Factor Receptor IgIII Loops in Cancer.

作者信息

Holzmann Klaus, Grunt Thomas, Heinzle Christine, Sampl Sandra, Steinhoff Heinrich, Reichmann Nicole, Kleiter Miriam, Hauck Marlene, Marian Brigitte

机构信息

Institute of Cancer Research, Department of Medicine I, Comprehensive Cancer Center, Medical University of Vienna, Borschkegasse 8a, 1090 Vienna, Austria.

出版信息

J Nucleic Acids. 2012;2012:950508. doi: 10.1155/2012/950508. Epub 2011 Dec 12.

DOI:10.1155/2012/950508
PMID:22203889
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3238399/
Abstract

Alternative splicing of the IgIII loop of fibroblast growth factor receptors (FGFRs) 1-3 produces b- and c-variants of the receptors with distinctly different biological impact based on their distinct ligand-binding spectrum. Tissue-specific expression of these splice variants regulates interactions in embryonic development, tissue maintenance and repair, and cancer. Alterations in FGFR2 splicing are involved in epithelial mesenchymal transition that produces invasive, metastatic features during tumor progression. Recent research has elucidated regulatory factors that determine the splice choice both on the level of exogenous signaling events and on the RNA-protein interaction level. Moreover, methodology has been developed that will enable the in depth analysis of splicing events during tumorigenesis and provide further insight on the role of FGFR 1-3 IIIb and IIIc in the pathophysiology of various malignancies. This paper aims to summarize expression patterns in various tumor types and outlines possibilities for further analysis and application.

摘要

成纤维细胞生长因子受体(FGFRs)1 - 3的免疫球蛋白III(IgIII)环的可变剪接产生了受体的b型和c型变体,基于它们不同的配体结合谱,这些变体具有明显不同的生物学影响。这些剪接变体的组织特异性表达调节胚胎发育、组织维持和修复以及癌症中的相互作用。FGFR2剪接的改变参与上皮 - 间质转化,这在肿瘤进展过程中产生侵袭性和转移性特征。最近的研究已经阐明了在外源信号事件水平和RNA - 蛋白质相互作用水平上决定剪接选择的调节因子。此外,已经开发出能够深入分析肿瘤发生过程中剪接事件的方法,并能进一步深入了解FGFR 1 - 3 IIIb和IIIc在各种恶性肿瘤病理生理学中的作用。本文旨在总结各种肿瘤类型中的表达模式,并概述进一步分析和应用的可能性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/627e/3238399/f833c601bf0a/JNA2012-950508.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/627e/3238399/900d0824911f/JNA2012-950508.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/627e/3238399/291dc0ad4769/JNA2012-950508.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/627e/3238399/377d395bc430/JNA2012-950508.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/627e/3238399/f833c601bf0a/JNA2012-950508.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/627e/3238399/900d0824911f/JNA2012-950508.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/627e/3238399/291dc0ad4769/JNA2012-950508.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/627e/3238399/377d395bc430/JNA2012-950508.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/627e/3238399/f833c601bf0a/JNA2012-950508.004.jpg

相似文献

1
Alternative Splicing of Fibroblast Growth Factor Receptor IgIII Loops in Cancer.癌症中成纤维细胞生长因子受体IgIII环的可变剪接
J Nucleic Acids. 2012;2012:950508. doi: 10.1155/2012/950508. Epub 2011 Dec 12.
2
Expression of fibroblast growth factor receptor-2 splice variants is developmentally and tissue-specifically regulated in the amphibian embryo.成纤维细胞生长因子受体-2剪接变体的表达在两栖类胚胎中受到发育和组织特异性的调控。
Dev Biol. 1994 Jul;164(1):173-82. doi: 10.1006/dbio.1994.1189.
3
Responsiveness of developing dental tissues to fibroblast growth factors: expression of splicing alternatives of FGFR1, -2, -3, and of FGFR4; and stimulation of cell proliferation by FGF-2, -4, -8, and -9.发育中的牙组织对成纤维细胞生长因子的反应:FGFR1、-2、-3和FGFR4剪接异构体的表达;以及FGF-2、-4、-8和-9对细胞增殖的刺激。
Dev Genet. 1998;22(4):374-85. doi: 10.1002/(SICI)1520-6408(1998)22:4<374::AID-DVG7>3.0.CO;2-3.
4
Alternative splicing of fibroblast growth factor receptors in human prostate cancer.人前列腺癌中成纤维细胞生长因子受体的可变剪接
Prostate. 2001 Feb 1;46(2):163-72. doi: 10.1002/1097-0045(20010201)46:2<163::aid-pros1020>3.0.co;2-t.
5
Addiction of mesenchymal phenotypes on the FGF/FGFR axis in oral squamous cell carcinoma cells.口腔鳞状细胞癌细胞中 FGF/FGFR 轴上的间充质表型成瘾。
PLoS One. 2019 Nov 4;14(11):e0217451. doi: 10.1371/journal.pone.0217451. eCollection 2019.
6
Role of fibroblast growth factor receptor-2 splicing in normal and cancer cells.成纤维细胞生长因子受体-2 剪接在正常细胞和癌细胞中的作用。
Front Biosci (Landmark Ed). 2018 Jan 1;23(4):626-639. doi: 10.2741/4609.
7
Exon III splicing switch of fibroblast growth factor (FGF) receptor-2 and -3 can be induced by FGF-1 or FGF-2.成纤维细胞生长因子(FGF)受体-2和-3的外显子III剪接转换可由FGF-1或FGF-2诱导。
Oncogene. 1998 Jul 9;17(1):67-76. doi: 10.1038/sj.onc.1201908.
8
Fibroblast growth factor receptor (FGFR) 3. Alternative splicing in immunoglobulin-like domain III creates a receptor highly specific for acidic FGF/FGF-1.成纤维细胞生长因子受体(FGFR)3。免疫球蛋白样结构域III中的可变剪接产生了一种对酸性成纤维细胞生长因子/FGF-1具有高度特异性的受体。
J Biol Chem. 1994 Apr 15;269(15):11620-7.
9
The choice between alternative IIIb and IIIc exons of the FGFR-3 gene is not strictly tissue-specific.FGFR-3基因的IIIb和IIIc外显子变体之间的选择并非严格具有组织特异性。
Biochim Biophys Acta. 1995 Nov 7;1264(2):238-42. doi: 10.1016/0167-4781(95)00156-b.
10
Fibroblast growth factor receptor 2: expression, roles, and potential as a novel molecular target for colorectal cancer.成纤维细胞生长因子受体2:表达、作用及作为结直肠癌新型分子靶点的潜力
Patholog Res Int. 2012;2012:574768. doi: 10.1155/2012/574768. Epub 2012 Jun 4.

引用本文的文献

1
The Lysine at Position 177 Is Essential to Limit the Inhibitory Capacities of Sprouty4 Protein in Normal and Cancer-Derived Cells.177位的赖氨酸对于限制Sprouty4蛋白在正常细胞和癌细胞中的抑制能力至关重要。
Int J Mol Sci. 2025 Jul 30;26(15):7353. doi: 10.3390/ijms26157353.
2
Classification and Quantification of Unproductive Splicing Events.非生产性剪接事件的分类与定量
Acta Naturae. 2025 Apr-Jun;17(2):75-85. doi: 10.32607/actanaturae.27572.
3
An FGFR-p53 developmental signaling axis drives salivary cancer progression.一条成纤维细胞生长因子受体(FGFR)-p53发育信号轴驱动唾液腺癌进展。

本文引用的文献

1
Fibroblast growth factor receptors as therapeutic targets in human melanoma: synergism with BRAF inhibition.成纤维细胞生长因子受体作为人类黑色素瘤的治疗靶点:与 BRAF 抑制的协同作用。
J Invest Dermatol. 2011 Oct;131(10):2087-95. doi: 10.1038/jid.2011.177. Epub 2011 Jul 14.
2
More than a splicing code: integrating the role of RNA, chromatin and non-coding RNA in alternative splicing regulation.超越拼接代码:RNA、染色质和非编码 RNA 在可变剪接调控中的作用整合。
Curr Opin Genet Dev. 2011 Aug;21(4):366-72. doi: 10.1016/j.gde.2011.03.004. Epub 2011 Apr 15.
3
Targeting fibroblast-growth-factor-receptor-dependent signaling for cancer therapy.
Oncogene. 2025 Jun 2. doi: 10.1038/s41388-025-03444-7.
4
Genetic ancestry concordant RNA splicing in prostate cancer involves oncogenic genes and associates with recurrence.前列腺癌中与遗传血统一致的RNA剪接涉及致癌基因并与复发相关。
NPJ Precis Oncol. 2025 Jan 29;9(1):30. doi: 10.1038/s41698-025-00817-9.
5
GPNMB is a novel binding partner of FGFR1 that affects tumorigenic potential through AKT phosphorylation in TNBC.GPNMB是FGFR1的一种新型结合伴侣,它通过TNBC中的AKT磷酸化影响致瘤潜能。
Cancer Sci. 2025 Feb;116(2):432-443. doi: 10.1111/cas.16419. Epub 2024 Nov 28.
6
Engineering growth factor ligands and receptors for therapeutic innovation.用于治疗创新的工程化生长因子配体和受体。
Trends Cancer. 2024 Dec;10(12):1131-1146. doi: 10.1016/j.trecan.2024.09.006. Epub 2024 Oct 10.
7
Deciphering the FGFR2 Code: Innovative Targets in Gastric Cancer Therapy.解析 FGFR2 密码:胃癌治疗的创新靶点。
Curr Oncol. 2024 Jul 29;31(8):4305-4317. doi: 10.3390/curroncol31080321.
8
FGFR2 and NOTCH1 Expression Inversely Correlated in Progressive Cutaneous Carcinogenesis in an Experimental Mouse Model.在实验性小鼠模型的进行性皮肤癌发生过程中,FGFR2和NOTCH1表达呈负相关。
J Pers Med. 2024 Jul 5;14(7):729. doi: 10.3390/jpm14070729.
9
Quantitative and qualitative differences in the activation of a fibroblast growth factor receptor by different FGF ligands.不同 FGF 配体激活成纤维细胞生长因子受体的定量和定性差异。
Cytokine Growth Factor Rev. 2024 Aug;78:77-84. doi: 10.1016/j.cytogfr.2024.07.002. Epub 2024 Jul 9.
10
Modulation of FGF pathway signaling and vascular differentiation using designed oligomeric assemblies.使用设计的低聚物组装体对 FGF 通路信号和血管分化进行调节。
Cell. 2024 Jul 11;187(14):3726-3740.e43. doi: 10.1016/j.cell.2024.05.025. Epub 2024 Jun 10.
针对成纤维细胞生长因子受体依赖性信号通路的癌症治疗。
Expert Opin Ther Targets. 2011 Jul;15(7):829-46. doi: 10.1517/14728222.2011.566217. Epub 2011 Mar 7.
4
The anti-tumor drug E7107 reveals an essential role for SF3b in remodeling U2 snRNP to expose the branch point-binding region.抗肿瘤药物 E7107 揭示了 SF3b 在重塑 U2 snRNP 以暴露分支点结合区域方面的重要作用。
Genes Dev. 2011 Mar 1;25(5):440-4. doi: 10.1101/gad.2009411.
5
Sudemycins, novel small molecule analogues of FR901464, induce alternative gene splicing.苏达霉素是 FR901464 的新型小分子类似物,可诱导选择性剪接。
ACS Chem Biol. 2011 Jun 17;6(6):582-9. doi: 10.1021/cb100356k. Epub 2011 Mar 7.
6
Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing.用于调节可变剪接的新型化学类型的特异性CLK抑制剂。
Chem Biol. 2011 Jan 28;18(1):67-76. doi: 10.1016/j.chembiol.2010.11.009.
7
TGF-β regulates isoform switching of FGF receptors and epithelial-mesenchymal transition.TGF-β 调节 FGF 受体的同工型转换和上皮-间充质转化。
EMBO J. 2011 Feb 16;30(4):783-95. doi: 10.1038/emboj.2010.351. Epub 2011 Jan 11.
8
Epigenetics in alternative pre-mRNA splicing.表观遗传学在可变剪接中的作用。
Cell. 2011 Jan 7;144(1):16-26. doi: 10.1016/j.cell.2010.11.056.
9
EGFR-mutated lung cancer: a paradigm of molecular oncology.表皮生长因子受体(EGFR)突变型肺癌:分子肿瘤学的一个范例
Oncotarget. 2010 Nov;1(7):497-514. doi: 10.18632/oncotarget.186.
10
The origin of ovarian carcinomas: a unifying hypothesis.卵巢癌的起源:一个统一的假说。
Int J Gynecol Pathol. 2011 Jan;30(1):12-21. doi: 10.1097/PGP.0b013e3181f45f3e.